Cayman Rolapitant; Purity- Greater Than Or Equal To 98%; Size- 10

Ceritinib is an inhibitor of anaplastic lymphoma kinase (ALK; IC₅₀ = 0.2 nM). It is selective for ALK over IGF-1R, InsR, STK22D, and FLT3 (IC₅₀s = 8, 7, 23, and 60 nM, respectively) as well as a panel of 25 additional kinases (IC₅₀s = >0.26 μM for all). Ceritinib inhibits the proliferation of Ba/F3 cells expressing the fusion protein nucleophosmin-ALK (NPM-ALK) or echinoderm microtubule-associated protein-like 4-ALK (ELM4-ALK; IC₅₀s = 0.02 and 0.021 μM, respectively), as well as several crizotinib-resistant NPM-ALK and ELM4-ALK mutants. It reduces tumor growth in an H2228 non-small cell lung cancer (NSCLC) rat xenograft model when administered at a dose of 10 mg/kg per day and induces tumor regression at 25 mg/kg per day. Ceritinib (25 and 50 mg/kg per day) also induces tumor regression in a Karpas299 lymphoma rat xenograft model. Formulations containing ceritinib have been used in the treatment of ALK-positive metastatic NSCLC.

WARNING This product is not for human or veterinary use.